TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9504626
Drug: Previously treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previously treated MM patients on treatment (n = 60)
Study: 9504626
Drug: Previously treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previously treated MM patients off treatment (n = 45)
Study: 3288846
Drug: Hormone substitution
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone substitution therapy with 17 beta‐oestradiol
Study: 12656701
Drug: gonadotropin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: gonadotropin‐releasing hormone agonist/estradiol group (n = 9)
Study: 12656701
Drug: gonadotropin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: gonadotropin‐releasing hormone agonist/placebo group (n = 12)
Study: 1540452
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clonidine and bupivacaine
Study: 25256937
Drug: 5.2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.2 μg of rhFSH
Study: 25256937
Drug: 6.9 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.9 μg of rhFSH
Study: 25256937
Drug: 8.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.6 μg of rhFSH
Study: 25256937
Drug: 10.3 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.3 μg of rhFSH
Study: 25256937
Drug: 12.1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.1 μg of rhFSH
Study: 25256937
Drug: 11 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 μg (150 IU) of follitropin alfa
Study: 25256937
Drug: rhFSH (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhFSH (various doses)
Study: 25256937
Drug: rhFSH (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhFSH (highest doses)
Study: 22733160
Drug: Intermittent androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent androgen deprivation (IAD) therapy with 11.25 mg leuprorelin acetate
Study: 15722066
Drug: NuvaRing (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: NuvaRing (15 microg of ethinylestradiol and 120 microg of etonogestrel daily)
Study: 15722066
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (150 microg of levonorgestrel and 30 microg of ethinylestradiol)
Study: 10500014
Drug: Psyllium (5.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (5.1 g twice daily)
Study: 31675992
Drug: Patient-reported data
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-reported data collection prior to randomisation and treatment
Study: 31675992
Drug: Monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring of participant dropout due to delays in treatment
Study: 26814240
Drug: HYD coarse
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYD coarse particles 60 mg
Study: 26814240
Drug: HYD fine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYD fine particles 60 mg
Study: 26814240
Drug: Hydrocodone powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone powder 60 mg
Study: 25453486
Drug: Guanfacine extended-release
Normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine extended-release (GXR) 0.05-0.12mg/kg/day (6-12 years: 1-4mg/day; 13-17 years: 1-7mg/day)
Study: 19843053
Drug: Palosuran 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palosuran 125 mg b.i.d. for 4 weeks
Study: 17264714
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg daily dexibuprofen
Study: 15891954
Drug: Pramlintide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide + insulin
Study: 15891954
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + insulin
Study: 11976561
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment after one month
Study: 9670263
Drug: Intraarterial hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial hepatic chemotherapy (IAHC) using IA FUDR
Study: 9670263
Drug: Intraarterial hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial hepatic chemotherapy (IAHC)
Study: 9670263
Drug: New protocols
Approvals — FDA: no, EMA: no, PMDA: no
Description: New protocols and combinations with systemic chemotherapy
Study: 7614642
Drug: Ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1 mg.kg‐1)
Study: 1854047
Drug: Thiopentone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (4 mg.kg‐1)
Study: 484813
Drug: Methohexitone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexitone 0.5 mg/kg
Study: 484813
Drug: Etomidate 0.067
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.067 mg/kg
Study: 11136909
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group 3
Study: 30682557
Drug: Severity of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severity of alcohol and drug use problems
Study: 29061010
Drug: Remifentanil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.1 μg·kg(‐1)·min(‐1) (Group S)
Study: 29061010
Drug: Remifentanil 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.3 μg·kg(‐1)·min(‐1) (Group L)
Study: 29061010
Drug: Remifentanil 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.3 μg·kg(‐1)·min(‐1) + lappaconitine 8 mg (Group G)
Study: 24499494
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg NRL001 (2 g suppository)
Study: 9085171
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of UST and PDN
Study: 8519040
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin (ECA) 325 mg/day
Study: 8519040
Drug: Buffered aspirin
Normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buffered aspirin (BA) 325 mg/day
Study: 8519040
Drug: Plain aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain aspirin (ASA) 325 mg/day
Study: 7306432
Drug: Imipramine 100
Normalized name: trimipramine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 100 mg
Study: 31752595
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment for insomnia (CBT-I)
Study: 29420925
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of HMB-FA
Study: 18764978
Drug: Controlled-release levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release levodopa (CR-LD)
Study: 18764978
Drug: Immediate-release levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Immediate-release levodopa (IR-LD)
Study: 24859356
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin
Study: 2665657
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b conjugate vaccine (standard dose)
Study: 2665657
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b conjugate vaccine (low dose)
Study: 2665657
Drug: Diphtheria, pertussis,
Normalized name: diphtheria, pertussis, tetanus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria, pertussis, and tetanus and polio vaccines only (Control)
Study: 30357310
Drug: Tailored, dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored, dose-dense (DD) epirubicin/cyclophosphamide (E/C) and tailored docetaxel (D) (tDD)
Study: 25814042
Drug: Tobramycin aerosol
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin aerosol (150mg/3ml) administered via the Easynose® device
Study: 20168104
Drug: Moxibustion (stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion (stimulating acupoint BL 67 daily for 2 weeks)
Study: 15998172
Drug: Fluticasone/salmeterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/salmeterol combination
Study: 9447537
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine and prilocaine cream (1 to 1.25 gm)
Study: 2847676
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion at high pressor dose (to increase diastolic pressure by 25 mmHg) in healthy volunteers
Study: 2847676
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion at low pressor dose (to increase diastolic pressure by 12-15 mmHg) in healthy subjects
Study: 2847676
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion at low pressor dose (to increase diastolic pressure by 12-15 mmHg) in patients with mild essential hypertension
Study: 30433852
Drug: Fluorouracil plus
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil plus cisplatin and radiation twice a day (FCT)
Study: 30433852
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily radiation plus gemcitabine (GD)
Study: 11565624
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg on days 1-7, 100 mg on days 8-14)
Study: 11565624
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg on days 1-7, 40 mg on days 8-14)
Study: 9630155
Drug: Single transperineal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single transperineal injection of botulinum toxin
Study: 7943829
Drug: ondansetron 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 0.15 mg.kg-1
Study: 7943829
Drug: metoclopramide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 0.5 mg.kg-1
Study: 7943829
Drug: droperidol 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 0.075 mg.kg-1
Study: 26431470
Drug: AFN-1252 200
Normalized name: AFN-1252
DrugBank: AFN-1252 (DB12658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFN-1252 200 mg single dose in fed versus fasted subjects
Study: 26431470
Drug: AFN-1252 200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFN-1252 200, 300, and 400 mg doses administered once-daily for 10 days
Study: 26431470
Drug: AFN-1252 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFN-1252 (all doses)
Study: 16430413
Drug: Morphine gel
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine gel (0.2 mg.kg(‐1), 1 mg.ml(‐1))
Study: 16430413
Drug: Morphine solution
Normalized name: morphine Injectable Solution
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine solution in saline (0.2 mg.kg(‐1), 1 mg.ml(‐1))
Study: 11107681
Drug: Glycoprotein IIb‐IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb‐IIIa receptor inhibitors
Study: 3862608
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) - 600 mg/day
Study: 3862608
Drug: Ambroxol (AMB)
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (AMB) - 90 mg/day
Study: 26774901
Drug: Intra-articular autologous
Normalized name: autologous cultured chondrocytes 1.2e+007 INTRA-ARTICULAR IMPLANT [CARTICEL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular autologous PRP injection
Study: 20056436
Drug: Remifentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (1 μg/kg bolus followed by a 0.5 μg/kg/min infusion for 30 minutes after induction but before sternotomy)
Study: 16507189
Drug: Inhalation induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation induction with sevoflurane
Study: 12846706
Drug: Intravenous induction
Normalized name: Intravenous induction agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous induction with thiopental
Study: 11764112
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group 2) - SEM examination without further treatment
Study: 8804878
Drug: Acetorphan (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetorphan (100-300 mg thrice daily)
Study: 8804878
Drug: Octreotide (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (50-150 micrograms thrice daily)
Study: 6698743
Drug: Topical imipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imipramine 0.05%
Study: 30193579
Drug: Prophylactic subcutaneous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic subcutaneous scopolaminebutyl
Study: 22129855
Drug: Ayurvedic zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic zinc (Jasad) tablets
Study: 19766734
Drug: Counselor initiated
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Counselor initiated tobacco quit line with 6 scheduled telephone sessions and 8 weeks of nicotine replacement therapy (NRT)
Study: 19766734
Drug: Participant initiated
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participant initiated tobacco quit line with 6 scheduled telephone sessions and 2 weeks of nicotine replacement therapy (NRT)
Study: 17344030
Drug: Hypericum extract
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extract (W55570) 300 mg t.i.d
Study: 9574879
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg, once daily for 7 days
Study: 30055591
Drug: Care and
Normalized name: ALCOHOL 0.65 mL in 1 mL TOPICAL GEL [Scentia Pro Care and Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care and treatment services for PLHIV
Study: 16984503
Drug: MMX mesalazine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMX mesalazine 2.4 g/day
Study: 16984503
Drug: MMX mesalazine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMX mesalazine 4.8 g/day
Study: 17882140
Drug: Caffeine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (50 mg)
Study: 10702430
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (4 ppm)
Study: 10702430
Drug: Prostaglandin E(1)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E(1) infusion (8 ng/kg/min)
Study: 7682395
Drug: Hyperthermo-chemotherapy (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermo-chemotherapy (Group B)
Study: 7682395
Drug: Chemotherapy (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Group A)
Study: 6135690
Drug: Clobazam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (mean daily dose: 59 mg)
Study: 6135690
Drug: Diazepam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (mean daily dose: 25 mg)
Study: 29303067
Drug: Modified tumescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified tumescent solution (gas‐liquid mixing tumescent solution)
Study: 29303067
Drug: Traditional tumescent
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional tumescent solution
Study: 9010687
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg digoxin
Study: 28962668
Drug: Tapering/discontinuation of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering/discontinuation of antipsychotic medication using a smartphone application to monitor early warning signs of psychotic relapse
Study: 28962668
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with antipsychotic medication
Study: 28962668
Drug: Tapering/discontinuation of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering/discontinuation of antipsychotic medication
Study: 28962668
Drug: Tapering/discontinuation and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering/discontinuation and maintenance therapy
Study: 18543484
Drug: Airening Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Airening Suppository (ARN)
Study: 16641323
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) adjunctive therapy at a target dose of 60 mg/kg/day
Study: 16641323
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) adjunctive therapy
Study: 14584069
Drug: Isocaloric low-fat/high-fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric low-fat/high-fiber diet (20% calories as fat, 25 g/day fiber, at least 8 servings of fruits/vegetables per day)
Study: 1740678
Drug: rhGM‐CSF (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM‐CSF (subcutaneous or intravenous administration)
Study: 31784702
Drug: topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical tacrolimus 0.1%
Study: 31784702
Drug: topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical cyclosporine 1%
Study: 28411246
Drug: GDF‐15 measured
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDF‐15 measured at 1 month after ACS (elevated GDF‐15 >1800 ng/L)
Study: 22230187
Drug: Part C
Normalized name: diluent,insulin aspart combination no.1 INJECTION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part C early intervention (EI) therapy
Study: 22230187
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (matched with EI therapy group)
Study: 11169930
Drug: Exemestane (EXE)
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane (EXE) 25 mg per day
Study: 10209938
Drug: Arginine infusion
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine infusion (20 g over 2 hours)
Study: 3252755
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg single oral dose
Study: 30218514
Drug: Premature Infant
Normalized name: Premature infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premature Infant Oral Motor Intervention (structured stimulation)
Study: 29507779
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (GBE) with 100 mg aspirin daily
Study: 29507779
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin daily (Control)
Study: 23591306
Drug: I-gel and
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-gel and Endotracheal intubation
Study: 21072235
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose rifampicin (SDR)
Study: 21072235
Drug: Standard multidrug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multidrug therapy (MDT) program with additional chemoprophylaxis
Study: 18946448
Drug: Short wave
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short wave diathermy (SWD) and non-steroidal anti-inflammatory drugs (NSAID)
Study: 17184455
Drug: 2% glacial
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% glacial acetic acid, 0.1% dexamethasone and 3250 U/ml of neomycin sulphate
Study: 14740951
Drug: DENV candidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: DENV candidate vaccines
Study: 14740951
Drug: DENV-1, DENV-2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DENV-1, DENV-2, DENV-3 candidate vaccines
Study: 14740951
Drug: DENV-2, DENV-3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DENV-2, DENV-3, DENV-4 vaccine candidates
Study: 10952481
Drug: Benfotiamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfotiamine (100 mg)
Study: 10952481
Drug: Thiamine nitrate
Normalized name: Thiamine nitrate
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine nitrate (100 mg)
Study: 9278568
Drug: Beta-carotene (0.11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (0.11 mmol / 60 mg)
Study: 9278568
Drug: Combined dose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dose of beta-carotene and lycopene (0.11 mmol each)
Study: 31648564
Drug: Prednisone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (5 mg/kg) for 4 weeks
Study: 31648564
Drug: Prednisolone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (5 mg/kg) for 4 weeks
Study: 31648564
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of prednisone (20 mg for 5 days)
Study: 31648564
Drug: Increasing concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing concentrations (0-200 ng/mL) of prednisone or prednisolone
Study: 31648564
Drug: GC-receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GC-receptor antagonist (RU486)
Study: 23520150
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH; tinzaparin)
Study: 23520150
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (tinzaparin plus warfarin for ≥12 weeks at home)
Study: 21538451
Drug: Generic drug
Normalized name: CELECOXIB 200 mg ORAL CAPSULE [Generic drug]
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic drug
Study: 21538451
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug
Study: 17823445
Drug: Soybean isoflavones
Normalized name: Soybean isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean isoflavones with inulin (3.66 g)